These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 3996561)

  • 21. [The oral liquid form of vinburnine: biopharmaceutics].
    Sado PA; Gibassier D; Leverge R
    J Pharm Belg; 1989; 44(1):50-9. PubMed ID: 2724048
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic aspects of the sublingual administration of vincamine.
    Aiache JM; Delatte MC; Leblanc PP; Kantelip JP; Gomeni R; Steimer JL
    Biopharm Drug Dispos; 1990; 11(4):279-309. PubMed ID: 2340347
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Agents to improve cerebrovascular circulation and cerebral metabolism--brovincamine].
    Maeda T
    Nihon Rinsho; 1985 Feb; 43(2):389-91. PubMed ID: 3889412
    [No Abstract]   [Full Text] [Related]  

  • 24. [Autoradiographic demonstration of the passage of vincamin through the blood-brain barrier].
    Sprumont P; Lintermans J
    Fortschr Med; 1982 Mar; 100(11):471-5. PubMed ID: 7076076
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [On the pharmacokinetics of vincamine after i.v. and oral application to the dog (author's transl)].
    Laufen H; Juhran W; Fleissig W; Götz R; Scharpf F; Bartsch G
    Arzneimittelforschung; 1977; 27(6a):1255-64. PubMed ID: 20113
    [No Abstract]   [Full Text] [Related]  

  • 26. [Fluorescence assay and pharmacokinetics of vincamine in rats (author's transl)].
    Iven H; Siegers CP
    Arzneimittelforschung; 1977; 27(6a):1248-54. PubMed ID: 578449
    [No Abstract]   [Full Text] [Related]  

  • 27. [Blood levels of vincamine. Comparative study of vincamine in delayed and immediate actions].
    Balcazar de Aztegui MD; Cruz Ramirez J
    Prensa Med Mex; 1978; 43(1-2):61-3. PubMed ID: 704535
    [No Abstract]   [Full Text] [Related]  

  • 28. [Application of multicompartimental analysis to the pharmacokinetics of vincamine in man].
    Ventouras K; Balant L; Revillard C; Buri P
    Pharm Acta Helv; 1977; 52(5):97-105. PubMed ID: 928474
    [No Abstract]   [Full Text] [Related]  

  • 29. [Vincamine concentrations in plasma and cerebrospinal fluid in patients following intravenous infusion (author's transl)].
    Siegers CP; Heiss WD; Kohlmeyer K
    Arzneimittelforschung; 1977; 27(6a):1274-7. PubMed ID: 578452
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vincamine TPS activity on glycoconjugate metabolism of the brain: effect on lysosomal enzymes.
    Federico A; D'Amore I
    Int J Clin Pharmacol Res; 1984; 4(4):277-9. PubMed ID: 6500774
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Controlled clinical study on the activity of vincamine-teprosylate in the so-called aging brain syndrome].
    Passeri M; Cucinotta D; Mancini M; Bia A; Palummeri E
    G Clin Med; 1982; 63(11-12):874-87. PubMed ID: 7182206
    [No Abstract]   [Full Text] [Related]  

  • 32. [In vitro dissolution test: evaluation criterion for prolonged release dosage forms vincamine example (author's transl)].
    Buri P; Doelker E; Boucherat J
    Schweiz Rundsch Med Prax; 1981 Jul; 70(29):1310-3. PubMed ID: 7279852
    [No Abstract]   [Full Text] [Related]  

  • 33. Pharmacokinetics of vinpocetine in humans.
    Vereczkey L; Czira G; Tamás J; Szentirmay Z; Botár Z; Szporny L
    Arzneimittelforschung; 1979; 29(6):957-60. PubMed ID: 582791
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro characterization of transport and metabolism of the alkaloids: vincamine, vinpocetine and eburnamonine.
    Fandy TE; Abdallah I; Khayat M; Colby DA; Hassan HE
    Cancer Chemother Pharmacol; 2016 Feb; 77(2):259-67. PubMed ID: 26666648
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cerebral antioedematous effect of Teproside and of some vincamine derivatives.
    Borzeix MG; Cahn J
    Int J Clin Pharmacol Res; 1984; 4(4):259-61. PubMed ID: 6500773
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Vincamine in cerebral arteriosclerosis: therapeutic effects evaluated clinically and by retinal fluoro-angiography].
    Ardito R
    Clin Ter; 1979 Mar; 88(5):461-12. PubMed ID: 466968
    [No Abstract]   [Full Text] [Related]  

  • 37. Acute i.v. vincamine teprosilate administration: quantified investigation in elderly subjects.
    Moglia A; Alfonsi E; Zandrini C; Pistarini C; Arrigo A
    Int J Clin Pharmacol Res; 1984; 4(4):303-6. PubMed ID: 6500777
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Syntheses of vinca alkaloids and related compounds. 104. A concise synthesis of (-)-vincapusine.
    Moldvai I; Gati T; Szantay C; Szantay C
    J Org Chem; 2006 May; 71(10):3768-72. PubMed ID: 16674048
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Treatment of sudden deafness. Apropos of the parenteral and peroral administration of Cerebroxine].
    Vincent Y; Ermens F
    Acta Otorhinolaryngol Belg; 1983; 37(1):88-94. PubMed ID: 6613569
    [No Abstract]   [Full Text] [Related]  

  • 40. Hydergine and vincamine derivative LD 4298 exhibit no anti-sickling properties in vitro.
    Roth E; Elbaum D; Godoy E; Nagel RL
    Nouv Rev Fr Hematol (1978); 1978; 20(4):611-9. PubMed ID: 752153
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.